This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (46)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Social Bookmarking   What's this?

A Case-Control Study

Ashfaq A. Marghoob, MD; Alfred W. Kopf, MD; Darrell S. Rigel, MD; Robert S. Bart, MD; Robert J. Friedman, MD; Sandhya Yadav, MD; Michelle Abadir, MD; Louis Sanfilippo; Mark K. Silverman, MD; Katrien A. Vossaert, MD

Arch Dermatol. 1994;130(8):993-998.

Abstract
Background and Design
There is an increased risk of developing cutaneous malignant melanomas (MMs) in patients with classic atypical-mole syndrome (AMS). This study compares the incidence of newly diagnosed MMs in patients with classic AMS (cases) with the incidence of newly diagnosed MMs developing in a population without classic AMS (control patients). The charts of 287 white patients with AMS and 831 white patients without AMS were reviewed for the occurrence of newly diagnosed invasive MMs during follow-up. Both cases and control patients were followed up regularly by total-body cutaneous examinations. The cumulative 10-year risk for developing newly diagnosed invasive MMs was calculated (life-table method) for each cohort.

Results
Of the 287 AMS cases, 10 developed a newly diagnosed invasive MM, resulting in a 10-year cumulative risk of 10.7%. Of the 831 control patients, two developed a newly diagnosed invasive MM, resulting in a 10-year cumulative risk of 0.62%.

Conclusion
Patients with classic AMS, regardless of the presence of a personal and/or family history of MM, are at significantly increased risk of developing invasive MMs compared with control patients.

(Arch Dermatol. 1994;130:993-998)

Author Affiliations
From the Ronald O. Perelman Department of Dermatology, New York (NY) University School of Medicine; Oncology Section, Charles C. Harris Skin and Cancer Pavilion, New York (NY) University Medical Center, Melanoma Cooperative Group, New York University (Drs Kopf, Rigel, Bart, Friedman, Yadav, Abadir, Sanfilippo, Silverman, and Vossaert); and the Department of Dermatology, State University of New York at Stony Brook (Dr Marghoob).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Identification of Incipient Tumors by Means of Sequential Dermoscopy Imaging: A New Way to Inflate the "Epidemic" of Melanoma?
Paolo Carli
Arch Dermatol. 2007;143(6):805.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Identification of Incipient Tumors by Means of Sequential Dermoscopy Imaging: A New Way to Inflate the "Epidemic" of Melanoma?
Carli
Arch Dermatol 2007;143:805-805.
FULL TEXT  

Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues
Hussein
J. Clin. Pathol. 2005;58:453-456.
ABSTRACT | FULL TEXT  

Dysplastic Nevi
Naeyaert and Brochez
NEJM 2003;349:2233-2240.
FULL TEXT  

Clinically Recognized Dysplastic Nevi: A Central Risk Factor for Cutaneous Melanoma
Tucker et al.
JAMA 1997;277:1439-1444.
ABSTRACT  

Prevention and Early Detection Strategies for Melanoma and Skin Cancer: Current Status
Koh et al.
Arch Dermatol 1996;132:436-443.
ABSTRACT  

Comparison Between Familial and Nonfamilial Melanoma in France
Grange et al.
Arch Dermatol 1995;131:1154-1159.
ABSTRACT  

Atypical Mole Syndrome and the Development of Melanoma
Journal Watch Dermatology 1994;1994:4-4.
FULL TEXT